Abstract
Peptide based vaccines offer practical advantages, but unmodified peptides usually require an adjuvant or delivery vehicle to promote immunogenicity. When peptides containing ovalbumin (OVA) derived CD4 and CD8 T cell epitopes were conjugated to 0.05 microm nano-beads, they gave strong immune responses and inhibition of growth of tumour cells expressing the CD8 T cell epitope with MHC class I. These responses were inducible with both high (50 microg) and low (5 microg) peptide doses after a single immunisation. The helper CD4 T cell epitope was unnecessary for induction of CD8 T cell or tumour challenge responses. However, the CD4 T cell epitope contained a B cell epitope and triggered strong antibody responses. This simple approach offers a convenient experimental tool and a potentially useful clinical method for peptide immunisation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antigens, Neoplasm
-
Epitopes / chemistry
-
Epitopes / immunology
-
Epitopes / pharmacology*
-
Histocompatibility Antigens Class I / chemistry
-
Histocompatibility Antigens Class I / pharmacology*
-
Histocompatibility Antigens Class II / chemistry
-
Histocompatibility Antigens Class II / pharmacology*
-
Mice
-
Mice, Inbred C57BL
-
Nanotechnology
-
Peptides / chemical synthesis
-
Peptides / chemistry
-
Peptides / immunology
-
Peptides / pharmacology
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / immunology
-
Vaccines, Conjugate / administration & dosage
-
Vaccines, Conjugate / immunology*
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology*
Substances
-
Antigens, Neoplasm
-
Epitopes
-
Histocompatibility Antigens Class I
-
Histocompatibility Antigens Class II
-
Peptides
-
Vaccines, Conjugate
-
Vaccines, Synthetic